Literature DB >> 18317755

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.

Karl-Johan Malmberg1, Yenan T Bryceson, Mattias Carlsten, Sandra Andersson, Andreas Björklund, Niklas K Björkström, Bettina C Baumann, Cyril Fauriat, Evren Alici, M Sirac Dilber, Hans-Gustaf Ljunggren.   

Abstract

Insights into the molecular basis for natural killer (NK) cell recognition of human cancer have been obtained in recent years. Here, we review current knowledge on the molecular specificity and function of human NK cells. Evidence for NK cell targeting of human tumors is provided and new strategies for NK cell-based immunotherapy against human cancer are discussed. Based on current knowledge, we foresee a development where more cancers may be subject to treatment with drugs or other immunomodulatory agents affecting NK cells, either directly or indirectly. We also envisage a possibility that certain forms of cancers may be subject to treatment with adoptively transferred NK cells, either alone or in combination with other therapeutic interventions.

Entities:  

Mesh:

Year:  2008        PMID: 18317755     DOI: 10.1007/s00262-008-0492-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

1.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 2.  NK cells: key to success of DC-based cancer vaccines?

Authors:  Eva Lion; Evelien L J M Smits; Zwi N Berneman; Viggo F I Van Tendeloo
Journal:  Oncologist       Date:  2012-08-20

3.  Investigation of deletion of 22pb in KIR2DS4 gene in a population of southern Brazil.

Authors:  Amanda Vansan Marangon; Jeane Eliete Laguila Visentainer; Gláucia Andréia Soares Guelsin; Samaia Laface Clementino; Cristiane Conceição Chagas Rudnick; Fabiano Cavalcante de Melo; Marco Antonio Braga; Ana Maria Sell
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

4.  TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer.

Authors:  Agnes Ling; Anna Löfgren-Burström; Pär Larsson; Xingru Li; Maria L Wikberg; Åke Öberg; Roger Stenling; Sofia Edin; Richard Palmqvist
Journal:  Oncoimmunology       Date:  2017-08-07       Impact factor: 8.110

Review 5.  Natural killer cell lines in tumor immunotherapy.

Authors:  Min Cheng; Jian Zhang; Wen Jiang; Yongyan Chen; Zhigang Tian
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

6.  Secretory TRAIL-Armed Natural Killer Cell-Based Therapy: In Vitro and In Vivo Colorectal Peritoneal Carcinomatosis Xenograft.

Authors:  Xinxin Song; Se-Hoon Hong; William T Kwon; Lisa M Bailey; Per Basse; David L Bartlett; Yong Tae Kwon; Yong J Lee
Journal:  Mol Cancer Ther       Date:  2016-04-12       Impact factor: 6.261

Review 7.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

Review 8.  Advantages and clinical applications of natural killer cells in cancer immunotherapy.

Authors:  Erik Ames; William J Murphy
Journal:  Cancer Immunol Immunother       Date:  2013-08-30       Impact factor: 6.968

9.  Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy.

Authors:  Damien Portevin; Mary Poupot; Olivier Rolland; Cédric-Olivier Turrin; Jean-Jacques Fournié; Jean-Pierre Majoral; Anne-Marie Caminade; Remy Poupot
Journal:  J Transl Med       Date:  2009-09-24       Impact factor: 5.531

Review 10.  Testing the theory of immune selection in cancers that break the rules of transplantation.

Authors:  Ariberto Fassati; N Avrion Mitchison
Journal:  Cancer Immunol Immunother       Date:  2009-12-22       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.